HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masashi Takano Selected Research

Cystadenofibroma

6/2012Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
4/2012Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
2/2008Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masashi Takano Research Topics

Disease

69Neoplasms (Cancer)
12/2022 - 02/2002
36Carcinoma (Carcinomatosis)
12/2022 - 03/2004
30Ovarian Neoplasms (Ovarian Cancer)
08/2021 - 05/2002
13Endometrial Neoplasms (Endometrial Cancer)
04/2022 - 03/2010
11Ovarian Epithelial Carcinoma
09/2021 - 05/2002
11Neoplasm Metastasis (Metastasis)
12/2019 - 12/2007
9Hypercalcemia (Milk Alkali Syndrome)
01/2016 - 07/2006
9Clear Cell Adenocarcinoma
06/2012 - 02/2008
8Hemorrhage
11/2021 - 12/2004
8Placenta Previa
01/2021 - 01/2016
7Endometriosis
05/2020 - 02/2008
6Adenocarcinoma
01/2021 - 02/2002
6Osteoporosis
10/2018 - 07/2006
6Breast Neoplasms (Breast Cancer)
07/2018 - 12/2008
6Osteosarcoma (Osteogenic Sarcoma)
01/2018 - 01/2012
5Uterine Cervical Neoplasms (Cancer of the Cervix)
06/2016 - 01/2003
4Ascites
01/2022 - 07/2009
3Postpartum Hemorrhage
11/2021 - 08/2017
3Rickets (Rachitis)
10/2021 - 10/2015
3Disease Progression
01/2021 - 12/2004
3Endometrioid Carcinoma
10/2020 - 01/2018
3Psoriasis (Pustulosis Palmaris et Plantaris)
10/2018 - 07/2006
3Leukemia
10/2018 - 09/2009
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2016 - 11/2013
3Carcinogenesis
01/2015 - 03/2010
3Cystadenofibroma
06/2012 - 02/2008
2Rupture
10/2018 - 08/2017
2Varicose Veins (Varicose Vein)
10/2018 - 06/2016
2Neutropenia
01/2018 - 05/2002
2Uterine Rupture
12/2017 - 08/2017
2Neuroendocrine Tumors (Neuroendocrine Tumor)
11/2017 - 07/2016
2Peripheral Nervous System Diseases (PNS Diseases)
09/2017 - 12/2004
2Squamous Cell Carcinoma of Head and Neck
01/2016 - 11/2013
2Pancreatic Neoplasms (Pancreatic Cancer)
11/2014 - 04/2013
2Liver Neoplasms (Liver Cancer)
10/2012 - 12/2011
2Hypoxia (Hypoxemia)
05/2012 - 02/2010

Drug/Important Bio-Agent (IBA)

22hydroxide ionIBA
10/2018 - 07/2006
21PlatinumIBA
02/2022 - 05/2002
19Proteins (Proteins, Gene)FDA Link
12/2022 - 10/2004
16Vitamin DFDA LinkGeneric
10/2021 - 07/2006
14Paclitaxel (Taxol)FDA LinkGeneric
09/2021 - 05/2002
1419- nor- 2- (3- hydroxypropyl)- 1,25- dihydroxyvitamin D3IBA
07/2018 - 12/2011
13Biomarkers (Surrogate Marker)IBA
11/2021 - 02/2010
13Cisplatin (Platino)FDA LinkGeneric
01/2021 - 05/2002
12Carboplatin (JM8)FDA LinkGeneric
09/2021 - 10/2004
11Irinotecan (Camptosar)FDA LinkGeneric
01/2018 - 01/2003
9Bevacizumab (Avastin)FDA Link
02/2022 - 11/2008
7Biological ProductsIBA
10/2020 - 05/2005
7OsteocalcinIBA
01/2018 - 09/2009
6Calcitriol Receptors (Calcitriol Receptor)IBA
10/2018 - 09/2009
5LigandsIBA
12/2022 - 02/2008
5taxaneIBA
10/2019 - 07/2009
5Therapeutic UsesIBA
01/2018 - 11/2011
5Indicators and Reagents (Reagents)IBA
01/2018 - 12/2004
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2020 - 11/2008
4GemcitabineFDA Link
01/2020 - 02/2013
4Cholecalciferol (Vitamin D3)FDA Link
11/2016 - 10/2012
4Pharmaceutical PreparationsIBA
01/2016 - 12/2004
3CA-125 Antigen (CA 125 Antigen)IBA
04/2021 - 08/2010
3liposomal doxorubicin (Doxil)FDA Link
01/2021 - 08/2011
3VimentinIBA
09/2020 - 07/2010
3Estrogen ReceptorsIBA
07/2018 - 01/2012
3nedaplatinIBA
01/2018 - 01/2003
2Formaldehyde (Formol)FDA Link
04/2022 - 02/2010
2pembrolizumabIBA
01/2022 - 01/2021
2lenvatinibIBA
01/2022 - 01/2021
2Immune Checkpoint InhibitorsIBA
01/2022 - 01/2021
2polysulfideIBA
08/2021 - 01/2021
2MesothelinIBA
04/2021 - 10/2020
21-dodecylpyridoxal (PLD)IBA
01/2021 - 08/2011
2Amino Acid Transport Systems (Amino Acid Transporter)IBA
09/2020 - 06/2019
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2018 - 05/2002
2CalciumIBA
01/2018 - 07/2006
22- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
01/2018 - 12/2006
2MineralsIBA
01/2017 - 01/2016
2Hemostatics (Antihemorrhagics)IBA
01/2017 - 01/2016
2Cytotoxins (Cytolysins)IBA
06/2013 - 04/2013
2Oxaliplatin (Eloxatin)FDA LinkGeneric
04/2013 - 02/2013
2ActininIBA
06/2012 - 12/2007
2DNA (Deoxyribonucleic Acid)IBA
04/2012 - 10/2011
2Cyclin AIBA
05/2010 - 11/2009
2Cyclin EIBA
05/2010 - 11/2009
2Complementary DNA (cDNA)IBA
10/2007 - 05/2006
1ParaffinIBA
04/2022

Therapy/Procedure

35Drug Therapy (Chemotherapy)
01/2022 - 05/2002
25Therapeutics
02/2022 - 05/2005
11Cesarean Section (Caesarean Section)
11/2021 - 01/2016
7Hysterectomy
04/2021 - 12/2004
6Combination Drug Therapy (Combination Chemotherapy)
01/2018 - 01/2003
4Radiotherapy
01/2021 - 01/2012
3Salpingo-oophorectomy
04/2021 - 06/2015
3Neoadjuvant Therapy
01/2020 - 07/2009
3Adjuvant Chemotherapy
12/2010 - 12/2006
2Catheters
10/2018 - 06/2016
2Uterine Artery Embolization
08/2018 - 08/2017
2Lymph Node Excision (Lymph Node Dissection)
06/2015 - 11/2011
2Operative Surgical Procedures
11/2012 - 05/2008
2Palliative Care (Palliative Therapy)
11/2012 - 10/2009
2Cytoreduction Surgical Procedures
02/2011 - 07/2009
1Immunotherapy
01/2022